Amenamevir

Drug Profile

Amenamevir

Alternative Names: ASP-2151; M5220

Latest Information Update: 04 Aug 2016

Price : $50

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; Maruho
  • Class Amides; Antivirals; Oxadiazoles; Small molecules
  • Mechanism of Action DNA helicase-primase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Herpes simplex virus infections; Herpes zoster

Most Recent Events

  • 01 Mar 2016 Mahuro completes a phase III trial in Herpes simplex virus infections in Japan (NCT02209324)
  • 01 May 2015 Maruho completes a phase I trial in volunteers in United Kingdom (NCT02403635)
  • 01 Apr 2015 Maruho completes a phase I drug-drug interaction study in Healthy volunteers in United Kingdom (NCT02321748)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top